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Abstract
Tuberous sclerosis complex (TSC) is characterized as a rare hereditary disorder impacting an
estimated 25,000-40,000 persons in the United States and 1-2 million persons worldwide (Song
et al., 2017). Individuals with TSC have extensive comorbidities that affect their health-related
quality of life, healthcare utilization, and expenditure. The current literature lacks documentation
on the impact of the various comorbidities and their association with healthcare utilization and
expenditures among individuals with TSC. The purpose of this dissertation study was to
examine the trends in healthcare utilization (emergency department and inpatient admission) and
expenditures that can be identified among individuals diagnosed with TSC, with and without
epilepsy. Multivariate analysis was conducted to compare the proportions of TSC patients with
epilepsy to the proportions of TSC patients without epilepsy, with regards to the use of inpatient
hospital (IP) care, emergency room (ER) use, and total expenditures. Among the 3,572 patients
analyzed, 65.5% of the study population were TSC patients with epilepsy, compared with 34.5%
of patients without epilepsy. Approximately 81% of the patients had between one to ten
comorbidities and the expected primary payer for most patients (67%), was public health
insurance (26% Medicare, and 40.7% Medicaid). The odds of hospital admission were nearly
two-fold higher among those with epilepsy (OR and CI). This finding indicated that increased
ED use among TSC patients with epilepsy may also lead to increased hospitalization. The overall
mean annual expenditure for ED visits by TSC patients without epilepsy was slightly lower than
that for patients with epilepsy. However, for an inpatient stay, TSC patients without epilepsy had
higher total expenditures ($63,520) compared with TSC patients with epilepsy ($40,248).
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Chapter 1: Introduction
Introduction to the Chapter
Tuberous sclerosis complex (TSC) is characterized as a rare hereditary disorder
impacting an estimated 25,000-40,000 persons in the United States and 1-2 million persons
worldwide (Song et al., 2017). TSC affects multiple organ systems, including the brain, kidneys,
lungs, heart, and skin. However, the manifestation of the disease is highly diverse and varies
significantly among individuals impacted (Northrup & Krueger, 2013). This rare genetic
disorder mutates in the TSC1 on chromosome 9q34 and the TSC2 on chromosome 16p13 (Toldo
et al., 2019; Curatolo, Bombardieri, & Cerminara, 2006), causing benign tumors in the brain,
kidneys, heart, lungs, liver, eyes, and skin (Sun et al., 2015). People with TSC have an increased
risk of developing epilepsy due to the disruption of a TSC gene expression in the brain, leading
to cerebellar atrophy, abnormal cellular growth, migration, and proliferation (Curatolo, 2015;
Moavero, Cerminara & Curatolo, 2010). There is significant variability in the clinical
presentation of TSC based on the characteristics associated with the onset of lesions coupled
with neurological manifestations, such as epilepsy and neurodevelopmental disorders
(Almobarak et al., 2018; Hallett et al., 2011).
Although various types of comorbidities (benign neoplasm of the kidney, malignant
neoplasm of the brain, epilepsy, autism, ulcerative colitis, and mood disorders) occur in
individuals with TSC, neurological disease (disorders of the nervous system) is arguably the
most important clinical issue. Epilepsy is one of the most common comorbid conditions among
individuals with TSC, with an onset of seizures occurring during the first year of life (Nabbout et
al., 2019). Current estimates suggest 80-85% of all TSC patients develop epileptic seizures, with
two-thirds who are not responsive to antiepileptic treatment (Curatolo et al., 2018; Overwater et
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al., 2015; Moavero, Cerminara, & Curatolo, 2010). The multiple comorbidities associated with
TSC and its effects on various organ systems indicate a significant health care and disease
burden, as well as a substantial economic burden on individuals, their families, and society.
Statement of the Problem
TSC inflicts a burden on society by imposing a significant toll on both the individuals
who have the condition and their families and caregivers. Individuals with TSC are at risk of
poor health outcomes; however, those associated with epileptic seizures are at an even greater
risk of poor health outcomes, along with constant use of health care and higher health-care costs.
The burden of disease management for TSC is well established in the literature; however,
there is limited available evidence of healthcare utilization and expenditure. In a systematic
review of the TSC literature, Hallett et al. (2011) concluded there is limited economic and
humanistic outcome research in this population, representing an important knowledge gap in the
cost of illness and treatment.
The goal of this dissertation study is to quantify and compare healthcare utilization and
expenditure among individuals diagnosed with TSC with and without epilepsy. Factors
including socio-economic status, clinical impact, and cost-effectiveness of treatment will be
explored. More importantly, understanding the profile and cost of healthcare utilization of these
individuals using real-world data is critical for (a) quantifying the existing burden on the
healthcare system, (b) identifying areas of sub-standard care for various comorbidities associated
with this disorder, (c) estimating future healthcare utilization and expenditures, and (d) bridging
the gap in currently published literature.
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Research Question
This dissertation study examined and compared healthcare utilization and expenditures
among individuals diagnosed with TSC, with and without epilepsy. The central guiding
questions to be examined in this study are as follows:
Question: What trends associated with healthcare utilization (emergency department use
and inpatient admissions) and expenditures can be identified among individuals
diagnosed with TSC with and without epilepsy?
Aim 1: To determine the healthcare utilization (inpatient and emergency
department) among individuals diagnosed with TSC with and without epilepsy.
Aim 2: To determine the specific costs associated with the care of these
individuals.
Aim 3: To determine the prevalence and impacts of predisposing comorbidities on
hospital admissions and expenditures among individuals with TSC who are
diagnosed with epilepsy.
Aim 4: To determine the socio-demographic and patient dispositions among
individuals with TSC that are associated with epilepsy.
Relevance and Significance
TSC is characterized as a rare hereditary disorder impacting an estimated 25,000–40,000
persons in the United States and 1–2 million persons worldwide (Song et al., 2017). Individuals
with TSC have an increased risk of developing epilepsy, which is considered as one of the most
common comorbid conditions. Although seizures are a hallmark manifestation of TSC, there is a
paucity of data in the public domain characterizing healthcare resource utilization and
expenditure in the TSC population.
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Little has been published in the last 10 years describing healthcare utilization and
expenditure burden of TSC and even less for individuals with comorbid epileptic seizures. A
search of the literature on healthcare utilization and expenditures of individuals with TSC
associated with epilepsy resulted in locating few publications: two studies conducted in the
United States, one in the United Kingdom, and one in Sweden. The absence of robust literature
of direct and indirect costs associated with TSC, and specifically in conjunction with epilepsy,
prevents an accurate assessment of the economic burden (Hallett et al., 2011)
Lennert et al. (2013) characterized resource utilization in a small cohort over 5 years in
patients with TSC and associated seizures in the US. This study revealed that hospitalization
was common in 83.2% of TSC patients, with a mean of 0.50 per year/patient and an average
length of stay of 6.22 days. Furthermore, neurologic-related hospitalizations accounted for a
mean number of 0.28 per year/patient and an average stay of 6.03 days (Lennert et al., 2013). A
similar study conducted recently in the US to examine TSC health care utilization based on the
National Inpatient Sample Database (NIS) using a dataset from the years 2000-2010 revealed
that of the 5,655 patients studied, 41.2% had epilepsy and an overall median total hospitalization
charge of $14,807 across all years (Wilson et al., 2016). A study conducted in the United
Kingdom examining the economic burden of TSC associated with epilepsy over a 3-year period
found patients incurred costs of £14,335 (U.S. equivalent of $18,449) on average, with a
significant proportion of costs attributed to inpatient admissions (Shepherd et al., 2017). Lastly,
a study conducted in Sweden to estimate the prevalence, manifestations, treatments, healthcare
utilization, and mortality of TSC patients with epilepsy found that patients with refractory
epilepsy (specifically those with infantile spasm) had the highest mean healthcare utilization
(Welin et al., 2017). Other relevant TSC studies examining healthcare utilization and
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expenditure include (a) a study in France by Chevreul et al. (2015) that estimated an average
annual cost of EUR 22,459 ( U.S. equivalent of $24,953) per patient for Systemic Sclerosis
(SSc), (b) Vekeman et al.’s (2015) study in the Netherlands examining individuals with TSC
associated with cyclin-dependent kinase (CKD) revealed an average expenditure of EUR 1,27531,916 ( U.S. equivalent of $ 1,566 – 39,215) annually in 2012, (c) a study in the United
Kingdom by Kingswood et al. (2016) that estimated the average expenditure of £12,681(U.S.
equivalent of $16,336) per person over the 3 years among individuals with TSC, and (d) a study
in the United States that estimated TSC patients with subependymal giant cell astrocytoma
(SEGA) had a mean expenditure of $85,397 (Sun et al., 2015), and TSC renal angiomyolipoma
(AML) patients with mean total healthcare costs ranging from $29,240-$48,499 (Song et al.,
2017).
The economic burden among individuals with TSC associated with epilepsy remains
poorly understood, with little evidence describing how the disease-associated costs impact
patients, caregivers, and society. The need for improvement in healthcare utilization and
expenditure related to the management and care for these individuals is essential to promote
adequate disease control and improve health and social outcomes. The findings from this
dissertation study will provide public health practitioners, health care providers, policymakers,
and other TSC stakeholders with healthcare utilization and expenditure data for this population.
The availability of such data ensures that evidence-based programs, supportive services, and
disease management meet the complex needs of individuals with TSC associated with epileptic
seizures.
Definition of Terms
The following definitions of terms are important in the understanding of this dissertation study:
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Epilepsy. Epilepsy is a chronic disease characterized by sudden recurrent and
unprovoked episodes of neurological disturbance, loss of consciousness, and convulsions
triggered by abnormal brain activity (Epilepsy Society, n.d.).
Seizure. A seizure is a sudden surge of electrical activity in the brain that usually affects
how an individual appears or acts for a brief period (Epilepsy Foundation, n.d.). According to
the epilepsy foundation, there are variations with the nature of seizures. These variations are due
to the particular lobe of the brain which controls different behaviors, movements, and
experiences (Epilepsy Foundation, n.d.).
Health Disparity. Health disparity is defined by the Centers for Disease Control and
Prevention as preventable differences caused by the burden of disease, poverty, environmental
threats, inadequate access to health care, and lack of opportunities to achieve optimal health
(CDC.gov, n.d.).
Healthcare Utilization. Healthcare utilization is the measure of a population’s use of
healthcare services such as utilization of hospital resources, personal home care resources, and
physician resources available to them (Manitoba Center for Health Policy, n.d.).
Socio-Economic Status (SES). SES is considered as the social standing or class
(educational level, income, and occupation) of an individual or group (American Psychological
Association, n.d.).
International Classification of Diseases, Ninth Revision (ICD-9). ICD9 is the official
system of assigning codes to diagnoses and procedures associated with hospital utilization in the
United States.
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Summary of the Chapter
This chapter introduced the research problem and gaps in the literature regarding
healthcare utilization and expenditure in TSC patients with epilepsy. It also presented the
research questions to be explored, highlighted the study’s implications for healthcare providers
and public policy, and described the importance of access to evidence-based data to aid
supportive services and disease management to meet the needs of the individuals impacted by
TSC.
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Chapter 2: Review of the Literature
Introduction to the Chapter
This literature review chapter presents an introduction to tuberous sclerosis complex and
epilepsy, a theoretical framework, and existing research that underpins the basis for this
dissertation study.
Tuberous Sclerosis Complex (TSC)
TSC was first described by von Recklinghausen when he presented a full-term stillborn
infant whose brain contained several sclerotic areas post-partum in 1862 (Roach, 2016).
Eighteen years later, a researcher named Bourneville characterized a baby’s brain pathology as
“sclérose tubéreuse des circonvolution cérébrales,” the name used to describe the disorder
(Roach, 2016). Bourneville in 1980 used the term “tuberous sclerosis of the cerebral
convolutions” when describing the potato-like appearance of the cerebral lesion observed
(Curatolo, Moavero, & de Vries, 2015).
TSC is considered one of the most common neurocutaneous disorders involving multiple
organ systems (DiMario, Sahin, & Ebrahimi-Fakhari, 2015). It presents variably during infancy,
childhood, and early adulthood in all ethnic groups and both sexes (DiMario, Sahin, & EbrahimiFakhari, 2015). This rare genetic disorder results in the mutation of the TSC1(encoding
hamartin) gene on chromosome 9q34, and TSC2 (encoding tuberin) gene on chromosome 16p13
(Toldo et al., 2019), causing benign tumors in the brain, kidneys, heart, lungs, liver, eyes, and
skin (Sun et al., 2015). Mutations in the TSC1 or TSC2 gene lead to disruption of the TSC1TSC2 intracellular protein complex (Curatolo et al., 2015), causing overactivation of the
mammalian target of rapamycin (mTOR) protein (responsible for the coordination of several
facets of cell functioning, including cell growth, metabolism, and proliferation; Slowinska et al.,
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2018).

mTOR, is a serine/threonine kinase found in two distinct complexes, mTOR complex

1(mTORC1) and mTOR complex 2 (mTORC2; Curatolo at al, 2015). mTORC1 regulates
protein synthesis, gene transcription, and cell cycle progression and survival, while mTORC2
has a role in mediating cytoskeletal dynamics (Franz & Capal, 2017). Abnormalities associated
with the mTOR pathway are believed to contribute to the development of many cancers, TSC,
and other neurologic disorders (Franz & Capal, 2017). Mutations in the TSC1 gene account for
10% of TSC cases, while the TSC2 gene is associated with an estimated 90% of the clinical
cases (Crino et al., 2006).
Prevalence, Clinical Characteristics, and Diagnosis of TSC
The occurrence of tuberous sclerosis complex is estimated to be as high as 1:5,800 live
births with a high mutation rate of 1:250,000 per gene, per generation (Northrup et al., 1999
[Updated 2018]). The population prevalence of TSC is estimated to be about 25,000-40,000
persons in the United States and 1-2 million persons worldwide (Song et al., 2017).
The clinical features of TSC manifest differently from person to person and are highly
variable and age-dependent (Roach, 2016). Although neurological and neuropsychiatric
manifestations (manifestations in the brain, seizures, intellectual disability, developmental delay,
and psychiatric illness) are the major sources of morbidity and mortality, most patients present
clinical findings of various comorbid manifestations (Curatolo et al., 2015). Tumors occurring in
the central nervous system (CNS) are among the leading causes of mortality and morbidity in
TSC patients (Northrup et al., 1999/2020). These brain tumors, found in TSC patients include
subependymal nodules (SENs), which occur in 80% of individuals, cortical dysplasia, occurring
in 90% of individuals, and subependymal giant cell astrocytomas (SEGAs), occurring in 5-15%
of all individuals (Northrup et al., 1999/2020]). Seizures affect more than 75% of TSC patients,

9

TUBEROUS SCLEROSIS COMPLEX, EPILEPSY
and about 50% have a developmental delay or intellectual disability (Curatolo et al., 2018;
Kingswood et al., 2017). Neuropsychiatric manifestations present in most individuals with TSC
are characterized as tuberous-sclerosis-associated neuropsychiatric disorders (TAND; Curatolo et
al., 2015). TAND includes manifestations that are behavioral, intellectual, and psychosocial.
Individuals with TSC are also at high risk for autism spectrum disorder (ASD), with recent
estimates of 16 - 61% (Kingswood et al., 2017)
Non-neurological manifestations, including dermatological manifestations (the
appearance of hypomelanotic macules (90%), angiofibromas (75%), fibrouscephalic plaques
(25%), ungual fibromas (20%), shagreen patches, and confetti skin lesions) are often the first
sign of TSC (Curatolo et al.,) with the skin affected in all TSC patients (Northrup et al, 1999
[Updated 2020]). In addition, cardiac rhabdomyomas, which occur in 60% of individuals with
TSC are considered to be part of the initial identifiable manifestations of the disorder and can
play a major role in the diagnosis of TSC (Curatolo et al., 2015). Manifestations in the kidney
(angiomyolipomas, cysts, renal cell carcinomas); heart (rhabdomyomas, arrhythmias); and lungs
(lymphangioleiomyomatosis, multifocal micronodular pneumonocyte hyperplasia) are other nonneurological manifestations present in individuals with TSC (Northrup et al, 1999/2018). Table
1 illustrates the various clinical characteristics and comorbidities associated with TSC.
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Table 1
Clinical Characteristics and Comorbid manifestations associated with TSC
Organ
System
Skin

Central
Nervous
System
(CNS)

Clinical
Manifestation
Hypomelanotic
macules

Definitions

Clinical Findings

Characterized as ("ash leaf
spots") patches of skin that
may appear anywhere on the
body and are caused by a
lack of melanin.

Hypomelanotic macules are
estimated to occur in
approximately 90% of
individuals with TSC
(Northrup et al, 1999/2018).

Confetti skin lesions

Stippled hypopigmentation,
typically on the extremities.
Characterized by red papules
on the malar region.

Confetti skin lesions occurs in
3% to ≤58% (Northrup et al,
1999/2018).

Facial
angiofibromas

An irregularly shaped,
slightly elevated soft skincolored patch, usually on the
lower back, made up of
excess fibrous tissue.

Facial angiofibromas occur in
approximately 75% of
individuals with TSC
(Northrup et al, 1999/2018).

Shagreen patches

Nodular or fleshy lesions that Shagreen patches occur in
arise adjacent to or from
approximately 50% of
underneath the nails.
individuals with TSC
(Northrup et al, 1999/2018).

Ungual fibromas

Fibrous growths that are
located around the
fingernails or toenails

Ungual fibromas occur in
20% overall but ≤80% in
older affected adults
(Northrup et al, 1999/2018).

Subependymal
nodules (SENs)-

Small nodular masses which
originate in the
subependymal region of the
lateral ventricles and
protrude into the ventricular
cavity.

Northrup & Krueger (2013),
estimate the prevalence of
SENs to occur in 80% of
individuals with TSC.

Cortical dysplasias

Malformation of the cerebral
cortex due to improper
migration of neurons in
utero.

Cortical dysplasias affect
approximately 90% of
individuals with TSC
(Northrup & Krueger, 2013).
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Kidneys

Heart

Subependymal giant
cell astrocytomas
(SEGAs)

Tumors commonly located
within the ventricles of the
brain.

SEGAs are estimated to occur
in 5%-20% of all individuals
with TSC (Kothare et al.
2014).

Epileptic Seizure

A sudden, uncontrolled
electrical disturbance in the
brain.

An estimate of >80% of
individuals with TSC has
been reported to have seizures
(Northrup et al, 1999/2018).

TSC-Associated
Neuropsychiatric
Disorder (TAND)

Characterized by the
manifestation of brain
dysfunction such as;
behavioral, psychiatric,
intellectual, academic,
neuropsychological, and
psychosocial difficulties.

An estimated 90% of
individuals with TSC exhibit
TAND features (de Vries et
al. 2018).

Autism Spectrum
Disorder (ASD)

A developmental disorder
that affects communication
and behavior.

Approximately 16% to 61%
of individuals with TSC
develop characteristics of
ASD with disease
manifestation occurring as
early as the age of nine
months (Kingswood et al
2017

Angiomyolipomas

Characterized as a benign
tumor of the kidney, can
grow such that kidney
function is impaired.

Renal disease occurs in an
estimated 80% of individuals
with TSC. Angiomyolipomas
and cysts are the most
common pathology observed
(Rakowski et al. 2006).

Renal Cystic disease

Characterized by the
development of numerous
fluid-filled cysts in the
kidneys.

Clinically detectable renal
cystic disease occurs in
approximately 50% of
patients with TSC (Dixon,
Hulbert & Bissler, 2010).

Cardiac
rhabdomyomas

A common primary tumor of
the heart in infants and
children that degenerates
over time and eventually
disappear.

Approximately 47%-67% of
individuals with TSC presents
Cardiac rhabdomyomas
(Northrup et al, 1999/2018).
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Lung

Lymphangioleiomyo Pulmonary disorder that
matosis (LAM)
typically presents in early
adulthood

LAM is estimated to occur in
approximately 34% of
females with TSC (Moss et
al., 2001)

Eye

Retinal hematomas

Retinal hematomas are
estimated in approximately
50% of individuals with TSC
(Rosser, Panigrahy &
McClintock, 2006).

Typically, asymptomatic and
are not progressive, but they
may obstruct vision in some
patients

A diagnosis of TSC can be made after careful clinical examination coupled with selected
organ imaging, laboratory testing, and genetic evaluation (DiMario, Sahin, & Ebrahimi-Fakhari,
2015). The criteria for TSC diagnosis were revised at the International TSC Consensus
Conference in 2012. The primary mode of diagnosis includes a genetic criterion as well as
clinical features. According to the revised diagnosis criteria (Table 3), a definitive diagnosis of
TSC can be made in the presence of a pathogenic TSC1 or TSC2 mutation, and a possible
diagnosis is made when either 1 major feature or greater than 2 minor features are present
(Curatolo et al., 2015). The presence of specific disease symptoms is rare; however, individuals
with TSC present several common characteristics that require further investigation, such as
(a)identification of family member with TSC, (b) identification of cardiac rhabdomyomas, (c)
postnatal identification of hypopigmented macules on the skin, and (d) the development of
seizure (DiMario et al., 2015).
Table 2
Diagnostic criteria according to the International Tuberous Sclerosis Complex Consensus
Conference
Diagnostic criteria for TSC
Definite diagnosis: presence of a pathogenic TSC1 or TSC2 or two major clinical features
Possible diagnosis: presence of either 1 major feature or greater than 2 minor features
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Major Criteria / Features
Skin/oral cavity

Hypomelanotic macules (n>3, at least 5 mm diameter)
Angiofibromas (n>3) or fibrous cephalic plaque
Ungual fibromas (n>2)
Shagreen patch

Central

Cortical dysplasias (includes tubers and cerebral white matter radial

Nervous

migration lines)

System

Subependymal nodules
Subependymal giant cell astrocytoma

Heart

Cardiac rhabdomyoma

Lungs

Lymphangioleiomyomatosis

Kidney

Angiomyolipomas (n>2)

Eyes

Angiomyolipomas (n>2)
Minor Criteria / Features

Skin/oral cavity

“Confetti” skin lesions
Dental enamel pits (n>3)
Intraoral fibromas (n>2)

Kidney

Multiple renal cysts

Eyes

Retinal achromic patch

Other organs

Nonrenal hamartomas
Tuberous Sclerosis Complex and Epilepsy

Epileptogenesis is a chronic process by which a normal brain, often triggered by genetics
or acquired factors, develops epilepsy (Curatolo et al., 2018). The presence of cortical tubers
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(dysplastic neurons, giant balloon cells, and glial components) are attributed to the development
of epilepsy in individuals with TSC (Jeong & Wong, 2016). Experimental studies suggest a
mutation of the TSC gene along with mTOR overactivation (Fig 1), resulting in the early
appearance of refractory seizures, TAND, and the encephalopathic process (Curatolo et al.,
2018).

Figure 1
TSC-associated seizures and TAND

Adapted from, Curatolo, P., Nabbout, R., Lagae, L., Aronica, E., ……. Jóźwiak, S. (2018).
"Management of epilepsy associated with tuberous sclerosis complex: Updated clinical
recommendations." European Journal of Paediatric Neurology.

Epileptic seizures affect 80-85% of individuals with TSC and are the most common
neurological comorbidity, with a significant incidence of morbidity and mortality (Almobarak et
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al., 2018; Nabbout et al., 2019). These seizures are not sudden occurrences, but rather a
progressive change that can be detected early in life through EEG synchronization and
appearance of focal or multifocal epileptiform activity (Cusmai et al., 2011). Clinical
investigations by researchers have indicated a high incidence of abnormalities in EEG patterns
and epileptiform features (Thiele, 2014). Experimental studies have suggested that the early
onset of epileptic seizures and the severity of the seizures may be attributed to a deficiency of
GABAergic interneurons, delayed GABA excitation, disruption of GABAergic interneuron
migration, and/or alterations in GABA-A receptors (Cusmai et al., 2011). While many types of
seizures are seen in individuals with TSC, infantile spasms are the most common and often
manifest during the first year of life (Curatolo et al., 2018). Other manifestations of epilepsy in
TSC patients include focal to bilateral tonic-clonic, atypical absence, myoclonic, and generalized
tonic-clonic seizures (Almobarak et al., 2018).
Diagnosis of Tuberous Sclerosis Complex Associated with Epilepsy
The diagnosis of TSC as accepted and recommended by the Tuberous Sclerosis
Consensus Conference in 2012 is based on the emergence of a pathogenic mutation (present in
75-90% cases) in either TSC1 or TSC2 gene (Slowinska et al., 2018). Other diagnostic criteria
for TSC include the presence of cardiac rhabdomyomas, dermatological findings with
hypomelanotic macules, ophthalmological changes, and renal manifestations (Slowinska et al.,
2018). In a large TSC registry study conducted by Ebrahimi-Fakhari et al. (2018), the median
age of diagnosis was one year. In most individuals, the diagnosis of TSC is made after the onset
of seizures (Slowinska et al., 2018). A study conducted by Jeong and Wong (2016)
demonstrated that brain activity characterized by cortical tuber hamartomas was linked to an
increased risk of epilepsy in individuals with TSC. Ebrahimi-Fakhari et al. (2018) found that
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CNS involvement with seizure disorders was the most common clinical symptom at diagnosis of
TSC and had a prevalence rate of 69.8%. Lastly, Chung et al. (2017) explained that the presence
of interictal epileptiform discharges (patterns of activity between seizures) and electrographic
seizure activity on EEG are precursors to the onset of seizures in individuals with TSC.
Treatment of Epilepsy Associated with Tuberous Sclerosis Complex
Individuals with TSC are at risk of poor health outcomes; those with epileptic seizures
have an even higher risk. The goal of epilepsy treatment in individuals with TSC is to prevent the
occurrence of seizures, thus maximizing the opportunity to improve cognitive development and
overall quality of life (Curatolo et al., 2018; Curatolo, Jozwiak, & Nabbout, 2012). Treatment of
epilepsy in individuals with TSC is considered difficult despite the availability of several options
in the management of the disease. A study conducted by Song et al. (2019) reported that nearly
all (92.3%) of the patients in the study received non-surgical and/or surgical treatment for the
management of epileptic seizures, with 99.5% receiving antiepileptic drugs (AEDs). This study
also reported a large proportion of patients who initiated multiple AEDs, corroborating an earlier
study by Overwater et al. (2015) that reported more than half of all patients studied had
refractory (uncontrolled or drug-resistant) epilepsy.
Although epilepsy treatment in individuals with TSC is refractory for most, treatment
options tend to be similar to those for non-TSC-associated diagnoses, including the use of AEDs
as well as nonpharmacologic approaches. AEDs such as topiramate, lamotrigine,
carbamazepine, valproic acid, and levetiracetam have all been found to be effective and welltolerated in this population (Canevini et al., 2018). Nonpharmacologic options include surgery,
ketogenic diet, and vagus nerve stimulation (Song et al., 2018; Curatolo, Jozwiak, & Nabbout.
2012).
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Pharmacologic Treatment Options
Antiepileptic drugs are commonly used in the management of epilepsy in TSC and are
considered to be first-line therapy (Song et al., 2018). Current literature indicates that one-third
of the children with TSC develop infantile spasms (Canevini et al., 2018), a rare epileptic
disorder that occurs in young children. The International TSC Consensus Conference, a panel of
TSC experts, recommended vigabatrin (VGB) as the first-line therapy for infants and AEDs with
c-aminobutyric acid (GABA)ergic mechanisms for older children (Overwater et al., 2015). In a
study conducted by Marques et al. (2019), the most common treatment for TSC patients with
epilepsy was GABAergic agents (e.g., vigabatrin), both in mono and combination therapy.
Vigabatrin, an inhibitor of GABA transaminase, is considered to be the most effective AED in
infants with spasm and other seizures (Canevini et al., 2018; Jozwiak et al., 2011). Other AEDs
such as valproic acid, levetiracetam, clobazam, lamotrigine, topiramate, oxcarbazepine,
carbamazepine, and adrenocorticotropic hormone have all been found to be effective in treating
epileptic seizures in individuals with TSC (Marques et al., 2019; Overwater et al., 2015). In an
open-label prospective patient chart review conducted by Overwater et al. (2015), the most
commonly used AEDs in TSC were valproic acid (85%), vigabatrin (61%), levetiracetam (46%),
carbamazepine (41%), and clobazam (41%). Literature from emerging studies also suggests that
the mechanistic target of rapamycin (mTOR) inhibitors may improve seizure and developmental
outcomes in TSC patients (Marques et al., 2019; Chung et al., 2017). mTOR activation can
result in increased neuroexcitability and seizures, thus mTOR inhibitors such as sirolimus
(rapamycin) and everolimus work by inhibiting mTOR signaling events (Curatolo et al., 2018).
Results from a randomized control trial conducted by French et al. (2016) to investigate
everolimus therapy for treatment-resistant seizures associated with TSC showed a significant
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reduction in seizure frequency and improvement in seizure control. Although there are various
AEDs available for the treatment of epilepsy in individuals with TSC, many of these individuals
develop seizure disorders that are pharmacoresistant. Table 3 illustrates the various
pharmacologic treatment options for individuals with TSC associated with epilepsy.
Table 3
Pharmacologic options for treatment of epilepsy associated with Tuberous Sclerosis Complex
Drug

Drug Class

Vigabatrin

Anti-epileptic, Gamma For use in treatment
amino acids and
resistant epilepsy,
derivatives
refractory complex
partial seizures, and
secondary generalized
seizures.

Adrenocorticotropic Carboxylic acids and
Hormone (ACTH derivatives
gel)
Everolimus

Valproic acid

Levetiracetam

Indication

For treatment and
management of seizure
disorders such as
infantile spasm

Treatment
Recommendation
Monotherapy in TSC
related spasm or focal
seizures.

Monotherapy for TSCrelated infantile spasm.

Protein Kinase inhibitor, For the treatment of TSC Adjunctive treatment of
Antineoplastic Agent
associated with seizures adult and pediatric
patients aged 2 years and
older with tuberous
sclerosis complex (TSC)associated partial-onset
seizures
Anticonvulsants

Anticonvulsants,
Carboxylic acids, and
derivatives

For treatment and
management of seizure
disorders such as
absence seizures, tonicclonic, and complex
seizures.

Monotherapy and
adjunctive therapy for
complex partial seizures
that occur either in
isolation or in association
with other types of
seizures

Used to treat partialonset seizures in adults
and children who are at
least 1 month old

Adjunctive therapy in the
treatment of partial-onset
seizures in adults and
children 4 years of age
and older with epilepsy.
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Carbamazepine

Anticonvulsant,
Benzazepines

Clobazam

Benzodiazepines,
Anticonvulsant.

Used for the treatment of Adjunctive therapy in
partial or complex partial both children and adults.
seizures

For treatment and
management of epilepsy
and seizures associated
with Lennox-Gastaut
syndrome, a difficult-totreat form of childhood
epilepsy.
Anticonvulsants,
Used either alone or in
Benzene, and substitutedcombination with other
derivatives
medications to treat
epileptic seizures in
adults and children.

Adjunctive therapy in
patients 2 years and older.

Oxcarbazepine

Anticonvulsant,
Carboxamide

Anticonvulsant drugs
used primarily for the
treatment of epilepsy.

Monotherapy or
adjunctive therapy in the
treatment of partial
seizures in adults with
epilepsy and as adjunctive
therapy in the treatment of
partial seizures in children
ages 4-16 with epilepsy.

Topiramate

Anticonvulsant, Antiepileptic,
Dioxolopyrans

Used for the treatment of Monotherapy for partialepilepsy in children and onset or primary
adults.
generalized in patients
over 2 years of age.
Adjunctive therapy for
partial-onset seizures
adults.

Lamotrigine

Adjunctive therapy for
seizures in patients ≥2
years of age and
monotherapy in adults
with partial seizures.

Non-Pharmacologic Treatment Options
The evaluation of nonpharmacologic options early during treatment is important due to
the refractory nature of AEDs among patients with epilepsy. Nonpharmacologic epilepsy
treatments shown to be effective in patients with TSC are the ketogenic or low glycemic index
diet, epilepsy surgery (Overwater et al., 2015), and vagus nerve stimulation (Connolly, Hendson,
& Steinbok, 2006).
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Epilepsy Surgery. Surgical treatment of epilepsy in children and adults with TSC has
gained significant interest in recent years, although surgical management proves to be complex
and challenging. The complexities are due to challenges associated with epileptogenic tuber
complexes merging subtly with each other, and involvement of more than one region of the brain
(Gupta, 2017). The effectiveness of epilepsy surgery has been shown in patients with refractory
epilepsies, with seizure freedom achieved in 50-60% of patients (Fohlen et al., 2018).

This is

consistent with a systematic review of literature by Jansen et al. (2007) that showed the
successful outcome of epilepsy surgery in patients with drug-resistant epilepsy and tuberous
sclerosis. Among these patients, the authors concluded that seizure freedom was achieved in
57% of the patients, and seizure frequency improved by >90% in 18% of patients (Jansen et al.,
2007). A long-term study conducted by Liang et al. (2017) also reported satisfactory seizure
freedom in 74.5% of the patients with TSC one year after surgery, 58.8% at five years after
surgery, and 47.8% ten years after surgery. To ensure better outcomes and seizure improvement
in TSC patients, candidates for epilepsy surgery should be carefully selected based upon a
comprehensive imaging and electrophysiological data, as well as invasive EEG recordings to
ensure the accurate identification of epileptogenic zones (Fohlen et al., 2018).
Ketogenic Diet. The ketogenic diet as a treatment for epilepsy and seizure control has
been documented in the medical literature for over 80 years.

New variations of the ketogenic

diet have emerged in the last decade, including the modified Atkins diet and the low-glycemicindex diet. The ketogenic diet can be an effective option in the management of epilepsy in
patients with TSC, particularly younger patients for whom surgery is not appropriate (Kossoff et
al., 2018; Martin‐McGill et al., 2018; Curatolo et al., 2012). The ketogenic diet has been shown
to have the ability to reduce mTOR activation in animal models, thus providing a scientific basis
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for its mechanism of action in TSC-associated seizures (Curatolo, 2018). Liu et al. (2018)
reported evidence of significant positive outcomes with the ketogenic diet for the treatment of
refractory epilepsy. In this study, analysis of patients with drug-resistant epilepsy showed that
the ketogenic diet was effective with 13% of the patients achieving seizure freedom and over
50% of the patients achieving seizure reduction by more than 50%. Similarly, a randomized
controlled trial conducted by Ijff et al. (2016) showed a positive cognitive and behavioral effect
of the ketogenic diet in children and adolescents with refractory epilepsy. For clinical
management of seizures, the ketogenic diet has been highly recommended for individuals and
specifically children who have failed more than two antiseizure medications (Kossof et al.,
2018).
Vagus Nerve Stimulation (VNS). VNS is a common neuromodulation based
intervention in patients with inadequately controlled seizures (Gonzalex, Yengo-Kahm, &
Englot, 2019). It is approved as an adjunctive therapy by the U.S. Food and Drug Administration
(FDA) for use in individuals 4 years and older with intractable partial-onset seizures. There is
limited literature regarding the use of vagus nerve stimulation in individuals with tuberous
sclerosis and refractory seizures. However, VNS has been proven to be an effective and safe
treatment for intractable epilepsy (Zamponi et al., 2010). In a small cohort study of individuals
with TSC, Parain et al. (2001) demonstrated the efficacy of using VNS as a mechanism for
seizure control. A similar study conducted by Elliott et al. (2009) in a small cohort of 19 patients
with refractory epilepsy and TSC further supports the use of VNS as a safe and effective
treatment option. In this study, 82% of the patients experienced a 67% reduction in seizures
(Elliott et al., 2009).
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Theoretical Framework
TSC disease etiology, manifestation, and treatment are well documented in the literature.
However, there is a scarcity of available evidence for healthcare utilization and expenditure in
this population. This dissertation study used a modified Anderson’s model of healthcare
utilization and its theoretical framework to determine the factors that contribute to healthcare
utilization and costs associated with illness and treatment.
Andersen’s model has been used extensively and is important in understanding the
reasons for excess healthcare utilization and expenditures when comparing groups of patients.
For the purpose of this study, the main constructs from Anderson’s model to be used include
environment, population or patient characteristics, and health service use. The use of healthcare
services among individuals with TSC with or without epilepsy (i.e., ED visits, inpatient
hospitalizations) and healthcare expenditures (i.e., expenditures for ED visits and inpatient
hospitalizations) was examined. A modified version of Anderson’s model for this dissertation
study is shown in Figure 2. The framework to be examined includes predisposing factors,
enabling factors, individual-specific healthcare needs, healthcare utilization, and costs
(Anderson, 1995; Graves, 2009).
Predisposing factors are socio-cultural characteristics (social structure, health beliefs, and
demographic factors) that exist before an illness (Anderson, 1995). When examining healthcare
utilization, it is important that enabling resources such as health facilities and health personnel
are available within the communities where people live and work (Anderson, 1995). Measures
such as health insurance and income are important factors when analyzing enabling resources for
healthcare utilization. Aday and Anderson (1974) explained that the framework for examining
access to care can be conceptualized as a process that includes an assessment of health policies
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(financing, education, and organization), characteristics of the healthcare system, the population
at risk to the utilization of the health services being rendered, and consumer satisfaction.
Among the predisposing factors, age and gender were examined in this dissertation
research. Insurance coverage (insured and uninsured), the health status of the patient, income,
and accessibility to care were also examined as enabling factors. Measures of need included
individual medical needs and perceived severity of the medical needs (co-existing
comorbidities). Healthcare utilization and costs of services, such as inpatient hospitalizations
and emergency department visits, are factors used to explain differences in outcomes (healthcare
utilization and expenditures) for individuals with TSC with and without epilepsy.

Figure 2
Modified Anderson Behavioral Model

Adapted from, Anderson, R. M. (1995). Revisiting the behavioral model of access to medical
care: Does it matter? Journal of Health Care and Social Behavior, 36, 1-10.
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Summary of the Chapter
The results of this literature review were congruent. Healthcare utilization and
expenditure in individuals with TSC and epilepsy are complex and not well-studied. Treatment
of TSC associated with epilepsy is considered difficult despite the availability of several options
in the management of the disease. Anderson’s model of healthcare utilization and its theoretical
framework were used to determine the factors that contribute to healthcare utilization and costs
associated with illness and treatment.
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Chapter 3: Methodology
Introduction to the Chapter
Estimating the economic burden associated with TSC can be challenging, due to the
complexity of the disease, including the diversity of the patient population and the heterogeneity
in the clinical disease manifestation, coupled with the existence of various comorbidities. This
chapter presents the methodology, research design, institutional review board (IRB) application
and approval process, and reliability and validity of the study, including information regarding
the data collection process, data preparation, and the strategy for data analysis.
Research Design
The research described in this dissertation was performed as a retrospective, cohort study,
to assess the differences in healthcare utilization and expenditures among individuals diagnosed
with TSC with and without comorbid epilepsy, in the United States. Five years of data, obtained
from the Nationwide Emergency Department Sample (NEDS), was used for this study. Each ED
visit included up to 15 diagnosis codes, based on the International Classification of Disease, 9th
revision, Clinical Modification (ICD–9–CM). According to the ED records, all patients with a
diagnosis of TSC (ICD 9-CM code 759.5) and epilepsy (ICD 9-CM code 345), in any position,
between 2010-2014 were abstracted.
Baseline characteristics, including each patient’s sociodemographic information and
comorbidities, were extracted, and the outcomes (healthcare utilization and expenditures) were
measured. All utilization rates and adjusted healthcare costs for the TSC population sample were
compared against those for patients with epilepsy as a comorbidity. The direct costs were
determined based on the total healthcare expenditures and derived from the sum of all direct
payments made for all healthcare services.
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Institutional Review Board and Data Use Agreement
An institutional review board (IRB) application was submitted to the Nova Southeastern
University IRB, and approval was received. After the receipt of IRB approval, data collection
and extraction were initiated. The Agency for Healthcare and Research Quality’s (AHRQ)
Healthcare Cost and Utilization Project (HCUP) nationwide Data Use Agreement (DUA) was
completed before receiving access to the NEDS data set.
Resources and Data Collection
This dissertation examined current trends in healthcare utilization (for both the
emergency department and inpatient admissions) and expenditures among individuals diagnosed
with TSC, both with and without epilepsy, using data from the NEDS database. The data files are
publicly available for download and use. NEDS data are distributed as fixed-width, ASCIIformatted data files. The NEDS database represents one of the largest all-payer ED databases,
containing national estimates for hospital-based ED visits, and was created as part of the AHRQ
Healthcare Cost and Utilization Project [Healthcare Cost and Utilization Project (HCUP), 2011].
NEDS contains information from approximately 28 million ED visits, at 980 hospitals, providing
a 20%-stratified sample of U.S. hospital-owned EDs. NEDS contains geographic, hospital, and
patient characteristic information, as well as data regarding the nature of hospital visits (e.g.,
common reasons for ED visits, acute and chronic conditions, and injuries), and discharge
information. The data are compiled from hospital billing records, from both state emergency
department databases (SEDDs) and state inpatient databases (SIDs). SIDs include information
regarding individuals who are initially treated in the ED and are subsequently admitted to the
same hospital. SEDDs contain information regarding those ED visits that do not result in hospital
admissions (i.e., treat-and-release visits and transfers to another hospital).
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These data facilitated the estimation of resource utilization associated with a relatively
rare condition. Using databases, such as NEDS, can help understand the extent and pattern of
inpatient and ED use among TSC patients and provides additional information regarding the
reasons for such visits, including the primary diagnosis received during the ED visit and the
outcome of the ED visit (e.g., treated and released, transfer to home health, or inpatient
hospitalization). An analysis of these data allowed associations among TSC, healthcare
utilization, and healthcare costs, to be inferred, using a previously unused method.
Identification of the Study Sample
The data used in this study were obtained from the NEDS database. TSC patients were
identified using the ICD 9-CM code 759.5. Data from the years 2010-2014 were obtained and
relevant dataset extracted. The NEDS core data files, which contain records for 100 percent of
ED visits, were linked with the NEDs supplemental inpatient file. A unique NEDS record
identifier (KEY_ED) can be used to link a patient’s NEDS core file with the corresponding
supplemental inpatient file. The inclusion criterion for this study was patients with TSC;
therefore, all patients with a TSC diagnosis (ICD 9-CM code 759.5) were included in this study.
Patients were excluded if the following data fields were missing from the dataset; age, gender,
and total cost/charges. Figure 3 presents a flow diagram showing how the sample was identified.
A total of 3,689 individuals met the inclusion criterion. After applying the exclusion criteria, a
final sample of 3,572 patients was identified.
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Figure 3
Identification of the study sample
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Reliability and Validity
For quantitative research, Creswell (2014) explained that employing accuracy verification
can result in meaningful interpretations of the data. For this dissertation research, the standards
used to stratify the data and the data collection methods will assure the data quality. To ascertain
the reliability of the data files, the NIS utilized a systematic sampling design to construct the
database. This sampling design was a self-weighted sample design, similar to random sampling
methods. The self-weighted sample design is considered to be efficient because it ensures that
the sample is representative of the population, based on several critical factors, including hospital
factors (hospital-unidentified, census division, ownership, urban-rural location, teaching status,
number of beds) and patient factors (diagnosis-related group, admission month). In addition, a
systematic sampling design reduces the margin of error for estimates. The NEDS data is based
on a stratified probability sample of hospital-owned EDs.
Data Analysis
SPSS version 24 was used for all statistical analyses. A descriptive analysis of the TSC
patient samples with and without epilepsy was performed. Continuous and categorical variables
were summarized using means and percentages, respectively. Multivariate analysis was
conducted to compare the proportions of TSC patients with epilepsy to the proportions of TSC
patients without epilepsy, with regards to the use of inpatient hospital (IP) care, emergency room
(ER) use, and total expenditures. The healthcare utilization of TSC patients, both with and
without epilepsy, was assessed by calculating the differences in the mean annual frequency of
healthcare services during the study period, for each type of service. The epilepsy-specific direct
healthcare costs were estimated as the differences in healthcare expenditures for all service types
between TSC patients with epilepsy and those without epilepsy. To measure the relationships
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among categorical variables, chi-square analyses were used (inpatient hospital admissions and
emergency room use), whereas t-tests were used to assess continuous outcome variables (length
of stay and annual expenditures) for the sub-group analyses of mean differences between TSC
patients with and without epilepsy. Based on the conceptual framework applied in this study, the
dependent variables will focus on the use of healthcare services among TSC patients with and
without epilepsy, including the number of ED visits, the number of inpatient hospitalizations,
and healthcare expenditures for ED visits and inpatient hospitalizations.
Variables of Interest
Dependent variables
TSC and epilepsy diagnoses were identified in NEDS, using the Clinical Classifications
Software (CCS) diagnosis codes, which were reported for each ED visit. The CCS is based on
the ICD-9-CM system, the accepted clinical mechanism for the identification of diagnoses and
claim submissions, which are tied to insurance reimbursement. The CCS maps ICD-9 codes
(which are extracted from the clinical ED encounter discharge abstract) with nearly 260
clinically meaningful diagnosis categories (Table 4). The CCS diagnosis code was selected as the
preferred variable for identifying TSC and epilepsy diagnoses for this analysis, based on clinical
applications and analytical feasibility. Although NEDS provides ICD-9-CM codes for up to 15
diagnoses per emergency department visit, we used only the first diagnosis listed for this
analysis. Senathirajah et al. (2011) explained that the first-listed diagnosis for an emergency
department record indicates the code for the diagnosis, condition, problem, or other reason for an
encounter/visit shown in the medical record that is thought to be chiefly responsible for the
services provided. Other dependent measures of utilization include trends for ED visits and
hospital inpatient days.
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NEDS provides information regarding the charges for ED and inpatient services, which
was used to identify the economic burden associated with ED visits and inpatient stays. Total ED
charges included both ED visits that resulted in “treated and released” patient outcomes and ED
visits that resulted in hospitalization at the same hospital. The total charges were adjusted for
inflation, relative to the value of the US dollar in 2014. To calculate the inflation adjustment
factor, the annual consumer price index (CPI) was utilized to transform/convert the total charges
into 2014 constant dollars. The CPI was obtained from the Bureau of Labor Statistics (Bureau of
Labor Statistics, US Department of Labor, 2019).
Table 4
ICD-9-CM Code Categorization
Category

CCS Code

Psychiatric

650-670

Cancer

11-47

Cardiovascular Disease

53, 96-118, 213

Endocrine Disease

48-52, 55, 58

Gastrointestinal Disease

135, 138-146, 148-155, 214

Respiratory Disease

122- 134

Infectious Disease

1-10, 76

Rheumatology

54, 201-206, 210

Pulmonary

56, 116

Autoimmune Disease

57

Hematologic Disease

59-64

Nervous System Disease

77-85, 94-95, 216, 227
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Ophthalmologic Disease

86-93

Vascular Disease

119-121

Nephrological Disease

156-166, 215

Gynecological /Obstetrics

167-196, 218-224

Dermatological Disease

197-200

Injury

226-236, 239-240

ICD-9-CM, International Classification of Disease, 9th revision, Clinical Modification; CCS,
Clinical Classification Software
Independent variables
Gender (male and female) and age (all ages reported) were selected as the predisposing
independent variables, based on the Anderson-Aday model. Age was categorized into infant (< 1
year), pre-school (1–5 years), grade-school (6–9 years), pre-adolescent (10–13 years), adolescent
(14–17 years), and adult (> 18 years) groups. Enabling variables included the health insurance
coverage reported as the primary payer for both the ED and inpatient stay (categorized as
Medicare, Medicaid, private, self-pay, no charge, or other) and socioeconomic status (median
household income for the patient’s zip code, assigned by HCUP). The disposition status from the
ED was also examined, categorized as discharged (patients treated and released from the ED),
admitted (patients admitted to the same institution), or other (transferred, left against medical
advice, died in the ED). The numbers and type of comorbidities reflected the need variables from
the model.
Summary of Chapter
This chapter described the data set that was used during this dissertation research and
how the research population was identified. This chapter also described the research measures
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and operationalization of variables and provided a profile of the study population and the
analytical methods used to test and answer the proposed research questions and aims.
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Chapter 4: Results
Introduction to the Chapter
This chapter presents the results of the statistical analyses performed to assess differences
in the health service utilization and expenditures between TSC patients with epilepsy and those
without epilepsy, as well as other predisposing, enabling, and need characteristics. This chapter
also presents the results of multivariate analysis, which was used to test the hypotheses and
identify the factors associated with health service utilization and expenditures.
Description of the Study Population
Tables 5 and 6 presents the characteristics of the study population, in terms of predisposing
(age, gender, and TSC diagnoses), enabling (expected primary payer), need (number of
comorbidities), and health behavior/service use (the type of ED event and disposition from ED)
factors. As shown in Table 5, among the 3,572 patients analyzed, 65.5% of the study population
were TSC patients with epilepsy, compared with 34.5% of patients without epilepsy. Among the
study population, 1,755 (49.1%) were men and 1,818 (50.9%) were women. Most patients (60.4%)
in the study population were adults (age > 18 years), whereas 7.3% were adolescents (age 14-17
years), 5.7% were pre-adolescent (age 10-13 years), 7.4% were grade school children (age 6-9
years), 14.6% were pre-school children (age 1-5 years), and 4.6% were infants (< 1 year).
Approximately 81% of patients had between one and ten comorbidities, 17% had between ten and
twenty comorbidities, and 2.1% had greater than twenty-one comorbidities. Over half of the
patients, 1,829 (51.2%), were treated and released from the ED after their initial hospital encounter.
In contrast, 1,609 (45%) of patients were admitted to the same hospital during their initial ED visit.
The expected primary payer for most patients (67%) was public health insurance (26% Medicare
and 40.7% Medicaid), whereas private insurance accounted for 26%. Patient location was
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categorized based on the urban-rural classification scheme for U.S. counties, developed by the
National Center for Health Statistics (NCHS), which emphasizes the distinction and differentiation
of counties associated with large metropolitan areas (counties near metro areas with populations 
1 million), separating these counties into two categories; large, “central” metro (akin to inner cities)
and large, “fringe” metro (akin to suburbs). Other NCHS classifications include medium
metropolitan, small metropolitan, micropolitan, and counties that are neither metropolitan nor
micropolitan. Approximately 31% (1,091) of patients lived in large, central, inner-city
metropolitan areas, 25% (897) lived in large suburban metropolitan areas, and 23% (808) lived in
medium metropolitan areas. Table 5 also presents the characteristics associated with the median
household income for patients, based on their zip codes. As shown in this table, the patient
distributions according to median household income were similar, with 891(25.2%) patients
categorized in the 0–25th percentile (poorest population), 912 (25.8%) patients in the 26–50th
percentile, 913 (25.9%) patients in the 51–75th percentile, and 774 patients in the 76–100th
percentile (the wealthiest population).
Table 5
Characteristics of the Study Population
N

%

3,572

100.0

TSC Patient with Epilepsy

2,338

65.5

TSC Patient without Epilepsy

1,234

34.5

Infant (< 1)

164

4.6

Pre-School (1–5)

520

14.6

Grade School (6–9)

265

7.4

Pre-Adolescent (10–13)

204

5.7

Adolescent (14-17)

262

7.3

2,157

60.4

All PREDISPOSING

Age (years)

Adult (18+)
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Gender
Male

1,754

49.1

Female

1,818

50.9

1-10 Diagnosis

2,891

80.9

11-20 Diagnosis

606

17

>21 Diagnosis

75

2.1

1-5 procedures

828

23.2

6-10 procedures

72

2.0

>11 procedures

10

0.3

ED visit in which the patient was treated and released

1,829

51.2

ED visit in which the patient was admitted to the same

1,609

45.0

124

3.5

10

0.3

1,756

49.1

Transfer to short-term hospital

124

3.5

Transfer to other: includes Skilled Nursing Facility,

61

1.7

12

0.3

1,609

45.0

10

0.3

Medicare

930

26.0

Medicaid

1,455

40.7

Private insurance

922

25.8

Self-pay

134

3.8

No Charge /Other

126

3.6

"Central" counties of metro areas with 1 million population

1,091

30.6

"Fringe" counties of metro areas with 1 million population

897

25.2

Number of Co-Morbid Diagnoses

Number of Procedures on ED Inpatient Record

Type of ED Event

hospital
ED visit in which the patient was transferred to another
short-term hospital
ED visit in which the patient was not admitted to the same
hospital, destination unknown
Disposition from ED
Routine

Intermediate Care Facility, Home Health Care (HHC)
Against medical advice (AMA)
Admitted as an inpatient to this hospital
Not admitted to this hospital, destination unknown
Expected Primary Payer

Patient Location: NCHS Urban-Rural Code
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Counties in metro areas with populations of 250,000–

808

22.7

Counties in metro areas with populations of 50,000-249,999

326

9.1

Micropolitan counties

258

7.2

Not metropolitan or micropolitan counties

176

4.9

0-25th percentile

891

25.2

26th to 50th percentile

912

25.8

51st to 75th percentile

913

25.9

76th to 100th percentile

774

21.9

999,999

Median Household Income for the Patient’s Zip Code

ED, Emergency department
The primary reasons and diagnoses (Table 6) reported for the initial hospital encounter
varied; however, more than one in five (26.1%) patients were diagnosed with epilepsy. Other
notable reasons or diagnoses associated with the initial ED visit included congenital anomalies
(6.0%), septicemia (2.9%), headache (2.5%), and pneumonia (2.5%).
Table 6
Primary Diagnosis at Initial Visit
N

%

Epilepsy; convulsions

933

26.1

Other congenital anomalies

216

6.0

Septicemia

102

2.9

Headache; including migraine

89

2.5

Pneumonia

89

2.5

Fluid and electrolyte disorders

78

2.2

Urinary tract infections

72

2.0

Other nervous system disorders

69

1.9

Abdominal pain

69

1.9

Other upper respiratory infections

61

1.7

Complication of device; implant or

60

1.7

Fever of unknown origin

58

1.6

Other gastrointestinal disorders

58

1.6

Nausea and vomiting

53

1.5

graft
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Other injuries due to external causes

53

1.5

Nonspecific chest pain

48

1.3

Open wounds of head; neck; and trunk

48

1.3

Superficial injury; contusion

45

1.3

Aspiration pneumonitis; food/vomitus

44

1.2

Other lower respiratory disease

41

1.1

Other connective tissue disease

39

1.1

Complications of surgical procedures

35

1.0

Mood disorders

35

1.0

Schizophrenia and other psychotic

32

.9

32

.9

or medical care

disorders
Skin and subcutaneous tissue infections

Characteristics Associated with Epilepsy
The characteristics of the study population, according to the presence or absence of
epilepsy diagnosis, are presented in Table 7. Among the study population, 65.4% (n = 2,338) had
at least one claim associated with an epilepsy diagnosis, whereas 34.5% (n = 1,234) had no
history of epilepsy diagnoses. Medicaid was the expected payor for the majority of TSC patients
with epilepsy and among all patients. The proportion of individuals with epilepsy was slightly
higher (35.2 %) among males than among females (30.2%). Similarly, epilepsy diagnoses
occurred more frequently (37.2%) among adults than among all other age groups. TSC patients
with epilepsy demonstrated a significantly higher number of comorbidities compared with those
without epilepsy. Specifically, 52.6% of TSC patients with epilepsy had an average of one to ten
comorbid condition, whereas 11.8% had eleven to twenty comorbid conditions, and 1% had
more than twenty-one comorbid conditions, as compared with 28.3% of TSC patients without
epilepsy with an average of one to five comorbid condition, 5.2% with ten to twenty comorbid
condition, and 1.1% with greater than twenty-one comorbid conditions. Overall, the prevalence
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of diseases associated with the central nervous system was higher among the study population
than other comorbidities. Specifically, 38.9% of patients with epilepsy had a comorbid disease of
the central nervous system. Respiratory diseases also had a high prevalence among the study
population, although to a lesser extent than neuronal conditions. The total number of surgical
procedures was significantly higher (66.9%) among TSC patients with epilepsy than among TSC
patients without epilepsy (33.3%).
Logistic regression was performed to ascertain the effects of age and gender on the
likelihood that the participants will have epilepsy. As shown in Table 7, age and gender were
associated with increased odds of epilepsy diagnosis. The model was able to explain 39.0% of
the variance in epilepsy diagnosis and correctly classified 65.4% of cases. Both age (except for
pre-school children aged 1-5 years) and gender were significant cofactors (P < .001). Females
had a 1.7-fold increase in the odds to experience epilepsy compared with males.
Table 7
Characteristics of the Study Population by Epilepsy Status
TSC without Epilepsy

ALL PREDISPOSING

TSC with Epilepsy

N

%

N

%

1,234

34.5

2,338

65.4

Logistic Regression on Epilepsy
Sig

OR

95% CI

Age (years)
Infant (<1)

63

1.8

101

2.8

Pre-School (1-5)

140

3.9

380

10.6

.479

0.888

(0.639–1.234)

Grade School (6-9)

74

2.1

191

5.3

.000

1.675***

(1.352–2.074)

Pre-Adolescent (10-13)

56

1.6

148

4.1

.003

1.541**

(1.159–2.047)

Adolescent (14-17)

74

2.1

188

5.3

.007

1.563**

(1.132–2.157)

Adult (18+)

827

23.2

1,330

37.2

.002

1.553**

(1.168–2.064)

Gender
Male

495

13.9

1,259

35.2

Female

739

20.7

1079

30.2

Primary Payer

40
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Medicare

303

8.5

627

17.7

Medicaid

434

12.2

1,021

28.6

Private Insurance

374

10.5

548

15.4

Self-Pay

70

2.0

64

1.8

No Charge/Other

50

1.4

76

2.1

1-10 Diagnoses

1,012

28.3

1,879

52.6

11-20 Diagnoses

184

5.2

422

11.8

>21 Diagnoses

38

1.1

37

1.0

Cancer

44

1.7

27

1.0

Cardiovascular Disease

84

3.2

58

2.2

Central Nervous System

89

3.4

1,029

38.9

Dermatological Disease

23

0.9

25

0.9

Endocrine Disease

24

0.9

85

3.2

Gastrointestinal Disease

79

3.0

106

4.0

Infectious Disease

50

1.9

83

3.1

Nephrological Disease

72

2.7

88

3.3

Ophthalmologic Disease

34

1.3

33

1.2

Psychiatric

57

2.2

89

3.4

Respiratory Disease

176

6.6

194

7.3

1-5 Procedures

263

28.9

565

62.1

>6 Procedures

40

4.4

42

4.8

0-25th percentile

306

8.7

585

16.6

26th to 50th percentile

334

9.5

578

16.4

51st to 75th percentile

298

8.4

615

17.4

76th to 100th percentile

273

7.7

501

14.2

Number of Comorbid
Diagnoses

Primary Diagnosis
Classification

Disease

Number of Procedures on
ED Inpatient Record

Median Household Income
for Patient’s Zip Code

Sig, significance; OR, odds ratio; 95% CI, 95% confidence interval. p < .05, **p < .01, and ***.
p < .001.
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Health Service Utilization
Health service utilization consisted of the use of inpatient services, the length of stay
among those with at least one inpatient admission, and the use of the emergency room. Among
the study group (Table 8), 51.2% (n = 1,829) had an initial hospital encounter in the ED, from
which they were treated and released, whereas 45.0% (n=1,609) were admitted as an inpatient to
the same hospital. A chi-square test of independence was performed, to examine the associations
between gender, age, and the outcome of ED visits according to epilepsy status. The association
between age and ED visit outcome was significant [X(5) = 37.4, p < .001]. Similarly, the
relationship between gender and ED visit outcome was also significant [X(1) = 22.3, p < .001].
Among the patients who were admitted as inpatients, the majority were adults (48.6%). The
proportion of TSC patients with epilepsy who were admitted to the same hospital during their
initial ED encounter was higher (32.7%) than the proportion of TSC patients without epilepsy
(12.3%).
Table 8
ED visit Outcomes
TSC without Epilepsy
N
%
1,234
34.5

ALL PREDISPOSING
ED visit in which the patient is treated and

764

21.4

TSC with Epilepsy
N
%
2,338
65.5

Sig

1,065

released

29.8
Sex

***
Male

312

17.1

554

30.3

Female

452

24.7

511

27.9

Age (years)

***

Infant (<1)

36

2.0

30

1.6

Pre-School (1-5)

113

6.2

207

11.3

Grade School (6-9)

53

2.9

114

6.2

Pre-Adolescent (10-13)

43

2.4

87

4.8
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Adolescent (14-17)

58

3.2

113

6.2

Adult (18+)

461

25.2

514

28.1

441

12.3

1,168

32.7

ED visit in which the patient is admitted to this
same hospital
Sex

***
Male

173

10.8

643

40

Female

268

16.7

525

32.6

Age

***
Infant (<1)

25

1.6

63

3.9

Pre-School (1-5)

20

1.2

133

8.3

Grade School (6-9)

18

1.1

64

4.0

Pre-Adolescent (10-13)

11

0.7

59

3.7

Adolescent (14-17)

14

0.9

67

4.2

Adult (18+)

353

21.9

782

48.6

Note: * = p < .05, **p < .01, and *** = p < .001. Sig, significance; ED, Emergency department
Table 9 compares inpatient admissions according to epilepsy status and the various
characteristics of the study population. Hospitalization was common among all patients;
however, a high proportion (72.6%) of hospitalized patients was observed among those with
epilepsy than among those without epilepsy.
To test the hypothesis that TSC patients with epilepsy are more likely to experience an
inpatient hospital admission than those without epilepsy, a logistic regression analysis was
performed. Table 9 presents the results of the logistic regression model for inpatient admissions.
The multivariate analysis substantiated the initial observations that patients with epilepsy were
more likely to experience a hospital admission, which was significant for grade school children,
adolescents, and adults (P ≤ .05). The odds of hospital admission were nearly twice as high
among those with epilepsy compared with those without epilepsy.
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Table 9
Inpatient Admissions by Epilepsy Status
TSC without
Epilepsy
N
%
441
27.4

ALL

TSC with Epilepsy
N
1,168

%
72.6

Logistic Regression on Inpatient
Admission
Sig
OR
95% CI

PREDISPOSING
Age (years)
Infant (<1)

25

1.6

63

3.9

Pre-School (1-5)

20

1.2

133

8.3

Grade School (6-

18

1.1

64

4.0

11

0.7

59

3.7

14

0.9

67

4.2

Adult (18+)

353

21.9

782

48.6

Male

173

10.8

643

40.0

Female

268

16.7

525

32.6

1.138

(0.704-1.838)

3.002

(1.845-4.883)

1.605

(.937-2.748)

**

2.421

(1.257-4.665)

**

2.160

(1.198-3.895)

***

1.897

(1.518-2.372)

.***

9)
Pre-Adolescent
(10-13)
Adolescent (1417)

Gender

Note: * = p < .05, **p < .01, and *** = p < .001. Sig, Significance; OR, Odds ratio; 95% CI,
95% confidence interval
Length of Inpatient Stay
Table 10 compares the inpatient length of stay, according to epilepsy status and the
characteristics of the study population. Overall, TSC patients with epilepsy had a mean length of
stay of 4.94 days, compared with a mean length of stay of 6.76 days among those without
epilepsy. A significant difference between groups was determined by an independent-samples ttest. The results showed that the 1.82 day difference in the mean length of stay was significant
[95% CI-825, 2.81; t(1750) = 3.59, P < .001].
To test the hypothesis that TSC patients with epilepsy would experience a longer average
length of stay than those without epilepsy, a regression analysis was performed (Table 10). The
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results of the regression analysis revealed that the length of stay for patients with epilepsy was
shorter than that for those without epilepsy. Both gender and age (6-8years old, 14-17 years old.
and 18 years and older) were significantly associated with length of stay (P ≤ .05).
Table 10
Length of Stay Among Hospitalized Patients

All
Epilepsy***
PREDISPOSING
Age (years)
Infant (<1)
Pre-School (1-5)
Grade School (6-9)
Pre-Adolescent (10-13)
Adolescent (14-17)
Adult (18+)
Gender
Male
Female

TSC without Epilepsy
Mean
N
6.76
501

TSC with Epilepsy
Mean
N
4.94
1251

6.81
3.26
10.76
2.21
6.88
7

26
34
21
14
17
389

3.74
3.41
4.93
4.1
4.28
5.44

66
151
73
68
75
818

9.43
5.11

191
310

5.21
4.6

688
563

Logistic Regression on LOS
Sig
OR
SE

***
*
**
**

1.180
2.017
1.684
2.221
2.062

(0.737-1.889)
(1.362-2.987)
(1.016-2.792)
(1.233-4.000)
(1.200-3.544)

***

2.067

(1.668-2.561)

Note: * p < .05, **p < .01, and *** p < .001. Sig, significance; OR, Odds ratio; SE, standard
error
Total Expenditures by Status
The total expenditures per person were transformed to a logarithmic scale and
standardized in constant dollars, using 2014 as the base year, to control for inflation associated
with medical care costs (Bureau of Labor Statistics, 2019). The results are presented in 2014
constant US dollars.
Tables 11 and 12 compare the mean annual expenditures for ED and inpatient stays (in
2014 constant dollars), according to epilepsy status and predisposing, enabling, and need
characteristics. Annual expenditures include the amounts paid by Medicaid, Medicare, private
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insurance, self-pay, and others. The overall mean annual expenditure for ED visits (Table 11) by
TSC patients without epilepsy was $2,345.51, compared to $2,433.17 for TSC patients with
epilepsy. An independent-samples t-test was performed to examine the mean difference in
annual expenditures for ED visits between TSC patients with and without epilepsy, which
showed that the mean ED expenditure difference of $87.67 was not significant [95% CI -198.94,
374.28; t(3285) = 0.60; P =.549]. TSC patients under the age of 18 who had epilepsy
experienced larger ED expenditures than those without epilepsy. The population with the largest
annual expenditures were patients with epilepsy whose primary classification diagnosis was
cardiovascular disease. These individuals spent approximately $6,000 annually, which was more
than twice the overall mean expenditure of $2,345-$2,433. High expenditures were also observed
for patients without epilepsy who also had a diagnosis of cardiovascular disease ($3,851),
although these patients spent less than their epileptic counterparts. Other diagnoses associated
with high expenditures included rheumatological conditions and conditions of the central
nervous system. For those individuals without epilepsy, gastrointestinal diseases were also
associated with high costs. Medicare and self-pay patients incurred higher costs than patients
using other methods of payment.
Table 11
Annual Emergency Department Expenditures According to Epilepsy Status

All
PREDISPOSING
Age (years)
Infant (<1)
Pre-School (1-5)
Grade School (6-9)
Pre-Adolescent (10-13)
Adolescent (14-17)

TSC without Epilepsy
Mean ($)
N
%
2,345.51
1,153
35.1

TSC with Epilepsy
Mean ($)
N
2,433.17
2,134

%
64.9

1,123.80
1,414.85
1,551.40
1,888.29
2,157.21

2,371.57
1,736.20
1,910.71
2,406.65
2,499.77

3.0
10.7
5.3
3.9
5.3

57
128
69
53
65

1.7
3.9
2.1
1.6
2.0
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Adult (18+)
Gender
Male
Female
Expected Primary Payer
Medicare
Medicaid
Private Insurance
Self-Pay
Other
Primary Diagnosis
Classification
Cancer
Cardiovascular Disease
Central Nervous System
Disease
Dermatological Disease
Endocrine Disease
Gastrointestinal Disease
Infectious Disease
Nephrological Disease
Ophthalmologic Disease
Psychiatric
Respiratory Disease
Rheumatology

2,704.06

781

23.8

2,708.90

1209

36.8

2,106.10
2,498.76

450
703

13.7
21.4

2,454.46
2,408.06

1155
979

35.1
29.8

2,763.28
1,820.03
2,555.06
2,759.91
2,163.12

287
402
347
67
41

8.7
12.2
10.6
2.0
1.2

2,770.90
2,130.12
2,575.22
2,796.79
2,350.99

584
922
495
60
68

17.8
28.1
15.1
1.8
2.1

2,456.84
3,851.35
2,665.84

39
79
84

1.6
3.3
3.5

1,721.15
6,033.04
2,518.33

25
50
927

1.0
2.1
38.3

1,477.91
2,341.88
2,891.52
1,724.51
2,538.80
2,137.88
2,090.61
1,812.22
2,933.82

20
22
74
48
69
33
53
160
22

0.8
0.9
3.1
2.0
2.9
1.4
2.2
6.6
0.9

2,661.63
2,197.08
2,224.36
1,872.42
2,299.46
1,011.22
1,882.75
1,891.37
2,759.38

19
79
96
78
79
31
82
179
11

0.8
3.3
4.0
3.2
3.3
1.3
3.4
7.4
0.5

Note: * = p < .05, **p < .01, and *** = p < .001.
For inpatient stays (Table 12), TSC patients without epilepsy had higher total
expenditures ($63,520) compared with TSC patients with epilepsy ($40,248). An independentsamples t-test was performed to determine whether a significant mean difference in annual
expenditures existed for inpatient stays between TSC patients with and without epilepsy. The
results showed a mean inpatient expenditure difference of $23,272.37, which was significant
[95% CI -12567.24, 33977.50; t(1740) = 4.26, P< .001]. Among the study population, males
without epilepsy experienced the highest total expenditures. Similarly, grade school children (6-9
years) without epilepsy had a larger inpatient expenditure ($133,524) than all other age groups.
High expenditures were also observed among infants without epilepsy ($99,202). TSC patients
without epilepsy who had primary diagnoses of cancer ($151,710) and infectious disease
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($166,726) had the greatest total expenditures. These individuals’ costs were more than double
the mean expenditure of $40,248–$63,520. High expenditures were also observed among
patients with epilepsy with diagnoses of cancer ($94,542) and infectious disease ($75,305),
although to a lesser extent than their non-epileptic counterparts. Medicare and Medicaid patients
without epilepsy incurred higher costs than all other patients in the study population.

Table 12
Annual Inpatient Expenditures According to Epilepsy Status

All
PREDISPOSING
Age (years)
Infant (<1)
Pre-School (1-5)
Grade School (6-9)
Pre-Adolescent (10-13)
Adolescent (14-17)
Adult (18+)
Gender
Male
Female
Expected Primary Payer
Medicare
Medicaid
Private Insurance
Self-Pay
Other
Primary Diagnosis
Classification
Psychiatric
Cancer
Cardiovascular Disease
Endocrine Disease
Gastrointestinal Disease
Respiratory Disease
Infectious Disease
Central Nervous System
Disease

TSC without Epilepsy
Mean ($)
N
%
63,520.45
497
28.5

TSC with Epilepsy
Mean ($)
N
40,248.08
1245

%
71.5

99,202.13
41,177.48
133,524.08
17,525.91
59,155.03
61,416.27

25
34
20
14
17
387

3.01.4
2.0
1.1
0.8
1.0
22.2

37,224.87
31,744.97
38,283.38
41,826.48
42,510.97
41,904.73

65
151
73
68
75
813

3.7
8.7
4.2
3.9
4.3
46.7

95,261.03
43,876.45

190
307

10.9
17.6

39,607.38
41,031.79

685
560

39.3
32.1

77,279.81
70,342.45
51,559.69
41,180.82
42,697.84

157
128
170
22
16

9.0
7.4
9.8
1.3
0.9

39,859.69
41,376.04
36,120.85
57,757.45
45,953.32

421
486
266
28
43

24.2
27.9
15.3
1.6
2.5

32,900.91
151,710.42
46,541.98
19,370.55
47,911.71
45,692.21
166,726.95
34,143.43

20
38
51
20
37
86
37
18

1.4
2.7
3.6
1.4
2.6
6.0
2.6
1.3

28,892.22
94,542.66
43,468.60
21,808.86
46,437.73
46,248.71
75,305.78
32,992.34

50
25
37
59
73
130
71
495

3.5
1.8
2.6
4.1
5.1
9.1
5.0
34.7
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Nephrological Disease

32,626.64

33

2.3

29,286.93

58

4.1

Note: * = p < .05, **p < .01, and *** = p < .001. Sig, significance
Summary of Chapter
This chapter presented the results of the analyses examining the characteristics associated
with TSC patients with and without epilepsy, health service use, and expenditures. Bivariate
analyses showed a higher proportion of patients with epilepsy used inpatient and emergency
room services compared with those without epilepsy. However, the length of stay was longer
among those who did not have epilepsy. The non-epilepsy group had higher mean expenditures
associated with inpatient stays than those with epilepsy. A larger proportion of epileptic TSC
patients experienced CNS comorbidities than non-epileptic patients.
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Chapter 5: Discussion & Conclusion
Introduction to the Chapter
This chapter presents a summary of the dissertation study findings, a discussion of the
findings, the relationship between this study and those reported in the existing literature, and the
important conclusions that can be drawn from this study. This chapter also presents the
implications for policy and practice, recommendations for further research, and the limitations,
and delimitations of this study. The present study examined the healthcare utilization and
expenditures associated with individuals diagnosed with TSC, comparing those with and without
epilepsy. Using a modified Behavioral Model for healthcare utilization as a conceptual
framework, the present study analyzed the healthcare utilization and expenditures data for TSC
patients with and without epilepsy, obtained from the Nationwide Emergency Department
Sample (NEDS). The study aimed to examine, analyze, quantify, and compare the healthcare
utilization and expenditures of individuals diagnosed with TSC, with and without epilepsy, in the
United States, using data obtained from the NEDS database.
Discussion
This dissertation study addressed the following questions regarding healthcare utilization
and expenditures among individuals diagnosed with TSC, with and without epilepsy:
Question: What trends associated with healthcare utilization (emergency department use
and inpatient admissions) and expenditures can be identified among individuals
diagnosed with TSC, with and without epilepsy
Aim 1: To determine the healthcare utilization (inpatient and emergency
department) among individuals diagnosed with TSC, with and without epilepsy.
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Aim 2: To determine the specific costs associated with the care of these
individuals.
Aim 3: To determine the prevalence and impacts of predisposing comorbidities on
hospital admissions and expenditures among individuals with TSC who are
diagnosed with epilepsy.
Aim 4: To determine the sociodemographic and patient dispositions among
individuals with TSC that are associated with epilepsy
This study contributes to the literature by providing information regarding the utilization
of ED and inpatient services among TSC patients, in addition to data regarding the associated
costs of treatment. A study conducted in 2013 showed that among TSC patients, the experience
of seizures was very strongly associated with hospitalization (Lennert et al., 2013); therefore, the
inpatient admissions and associated expenditures were expected to be high among TSC patients
with epilepsy.

Healthcare Utilization

Among the study population, the most common reasons for the initial ED visit were
associated with epilepsy and other congenital anomalies. TSC patients with epilepsy were
diagnosed with more comorbidities than those without epilepsy. Most ED visits were categorized
as treat and release. Among those admitted as inpatients to the same hospital, the proportion of
TSC patients with epilepsy was higher (72.6%) than the proportion of TSC patients without
epilepsy (27.4%). The odds of hospital admission were nearly two-fold higher among those with
epilepsy (OR and CI). This finding indicated that increased ED use among TSC patients with
epilepsy may also lead to increased hospitalization. Contrary to expectations, however, individuals

51

TUBEROUS SCLEROSIS COMPLEX, EPILEPSY
with epilepsy had a shorter average length of stay (4.94 days) than those without epilepsy (6.76
days). This result is consistent with the findings from an earlier study by Lennert et al. (2013),
which reported similar lengths of stay for neurologic-related hospitalization (6.03 days), compared
with the length of stay among the control cohort for TSC-related hospitalization (6.80 days). This
outcome could be attributed to the necessity of performing surgical procedures, comprehensive
diagnostic testing, and other interventions, which often require more specialized care and the
increased utilization of healthcare resources, leading to an increased length of stay. In addition, the
length of stay among this population may also be attributed to unmeasured differences in the
severity of comorbid conditions. Further research evaluating the clinical profiles and the drivers
associated with prolonged inpatient stays among these patients improve our understand and expand
the findings of this study.

ED and Inpatient Expenditures

This study also compared the mean total ED and inpatient charges between TSC patients
with and without epilepsy. The overall mean annual expenditure for ED visits by TSC patients
without epilepsy was slightly lower than that for patients with epilepsy. However, for an
inpatient stay, TSC patients without epilepsy had higher total expenditures than TSC patients
with epilepsy. Although individuals without epilepsy had higher average inpatient expenditures
than those with epilepsy, the absence of epilepsy as a comorbidity did not increase the odds of
being included in the highest expenditure group. The odds of high expenditures were increased
among patients with pre-existing conditions, such as cancer and infectious diseases. Grade
school (aged 6-9 years) TSC patients without epilepsy had higher annual expenditures than all
other age groups. Nearly half (46.3%) of TSC patients with epilepsy were covered by public
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health insurance (Medicare and Medicaid), compared with less than one-quarter (20.7%) of TSC
patients without epilepsy. Among all patients, a higher proportion (67%) had Medicaid as the
primary payer, suggesting that these patients were likely receiving disability compensation or
were considered to have low incomes. This finding also suggested that public payers account for
larger proportions of ED visits that lead to inpatient admissions among this population. This
outcome is consistent with a study conducted by Wen et al. (2017), which reported that ED visits
leading to inpatient admissions for more than 90% of pediatric epilepsy patients were covered by
Medicaid. To our knowledge, no studies among the TSC-specific health services research
literature has examined the demographic characteristics and costs among individuals on public
insurance, especially Medicare and Medicaid, even though this may describe a high proportion
of the TSC population.
Implications for Health Policy and Practice
Because TSC is frequently accompanied by comorbid health conditions, such as epilepsy
and other chronic physical illnesses, a patient may be treated by numerous specialists. Although
access to and the use of multiple healthcare providers is often perceived as good access to care,
this situation can also be associated with many challenges, including additional burdens on
caregivers and families. Policymakers should adopt and implement. Advocacy groups, such as
the TSC Alliance, have developed information to help individuals with TSC identify specialty
clinics and clinicians (TSC Centers of Excellence) and to actively engage with their physicians
and other health providers (tsalliance.org, n.d.). These resources provide tools to help TSC
patients and their families become active participants in their healthcare, by asking questions
about the relationships between conditions, medication interactions and side effects, and
facilitating communications between primary care physicians and specialists (tsalliance.org,
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n.d.). Despite the availability of these resources, additional resources and programs remain
necessary to improve patients’ access to these specialized clinics. A study conducted by Rentz et
al. (2015), reported that, although over 40 TSC Centers of Excellence have been designated in
the United States, almost three-fourths of adult patients and half of pediatric patients in their
study lived further than 100 miles away from a TSC clinic. The challenges of living with
multiple health conditions also indicate the need for continuous health education for TSC
patients and their caregivers, in addition to multidisciplinary medical team input (Northrup &
Krueger, 2013). Patients often face significant difficulties in identifying the right medical
expertise necessary to comprehensively and effectively manage their care. As TSC patients grow
from childhood into adulthood, care coordination among various specialties can be critical
during the transition from pediatric to adult healthcare services (Both et al., 2018). Care
coordination can include the inclusion and evaluation of the viewpoints of the patients and their
families, to gain insights into the difficulties associated with the care of these patients and the
development of interventions that might improve the transition process to adult services. One
possible solution for effective and efficient care coordination is the availability of facilities and
clinics capable of treating both children and adult TSC patients, which would ensure efficient
transitional healthcare and appropriate and continuous surveillance and disease management.
State agencies can provide support for the development and delivery of health education
programs and educational materials. For example, the Managing Epilepsy Well (MEW) network
is a Centers for Disease Control and Prevention (CDC) research center program that aims to
provide national leadership for the development, testing, and distribution of innovative selfmanagement programs and training for epilepsy professionals, families, and individuals affected
by epilepsy. Project UPLIFT, a program within the MEW network, provides self-management
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programs that aim to empower people with epilepsy to manage and improve their mental health
and quality of life. Similar programs can be expanded to include specialized and focus education
and training for individuals with epilepsy coupled with rare genetic diseases, such as TSC. The
results from this study can be used by policymakers and organizations to focus further
investigations into the costs associated with care management and care delivery patterns among
individuals with TSC.
Implications for Future Research
This analysis of health service utilization and expenditures among TSC patients with or
without epilepsy highlights areas of potential future research. First, additional studies, using
similar methods and other claims datasets, remain necessary to assess the generalizability of the
study findings. The present study documented the increased odds of inpatient hospitalizations
and emergency room use among TSC patients with epilepsy compared with those without
epilepsy. Future studies should examine patterns of repeated hospital events, which could
facilitate the identification of opportunities for the prevention of these events. Additional
analyses of race/ethnicity differences, outpatient services, medication use, and ambulatory care
among TSC patients, along with precise measurements of the various comorbidities, remain
necessary to better understand the healthcare utilization and expenditures among this population.
Research identifying barriers to medical and social service access can indicate specific targets for
policy solutions and ensure equitable access to healthcare.
The findings from this dissertation study have raised additional questions regarding the
factors that affect the lengths of hospital stays and annual expenditures. Future studies should
include all diagnoses, treatments, and interventions in the claims data and should explore other
comorbidity measures, especially given the unexpected result that TSC patients without epilepsy
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experienced significantly longer lengths of stay and increased mean inpatient expenditures than
patients with epilepsy, which may reflect unmeasured differences in the overall health status.

Limitations and Delimitations
To conduct this dissertation research, data were obtained from the largest, publicly
available, all-payer database, for the period 2010-2014. All individuals diagnosed with TSC,
either with or without epilepsy as a comorbidity, were included. Variations in demographic data
were expected but were not controlled for during this analysis. Limitations include selection bias,
which can occur because the outcomes being observed have already occurred at the time of
selection. In addition, the use of retrospective, secondary data presents limitations, due to the
lack of control in the selection of study variables and sampling and collection methods. Despite
many advantages, the NEDS data is limited because it uses discharge-level, rather than a personlevel, data. Therefore, multiple visits by individuals within the study population could not be
distinguished.
This dissertation study is delimited to individuals with TSC associated with epilepsy. The
decision to examine a specific data set and variables of interest also delimit the dissertation
study. The NEDS data contains encounter-level records, not patient-level records; therefore,
individual patients who visit the ED multiple times in one year may be present in the NEDS
database multiple times. No uniform patient identifiers are available that would allow a patientlevel analysis for the identification of individuals associated with more than one ED visit. The
NEDs dataset did not include prescription medication use or associated expenditures or
information regarding patient encounters with outpatient services and specialist clinics.
Therefore, these results may not reflect the experiences of those who used outpatient services
and specialist clinics, resulting in an incomplete assessment of healthcare utilization and
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expenditures. Missing values from the obtained data can compromise the quality of estimates,
resulting in bias and the inaccurate representation of inpatient and ED utilization patterns.
Finally, racial/ethnic differences could not be accounted for in this study, due to the lack of
information on race in the available data.
Conclusion
TSC inflicts a burden on society, imposing a significant burden on both individuals who
have the condition and their families and caregivers. Despite the availability of FDA-approved
medications for the treatment of TSC and its associated comorbidities, the results from this
dissertation study suggested significant healthcare utilization and expenditures among this
patient population. A better understanding of the utilization and cost patterns associated with
TSC would facilitate the efficient allocation of resources while improving overall care for these
patients.
TSC patients visit EDs for various reasons, beyond those associated with their primary
condition or disease. ED visits among TSC patients with epilepsy were associated with increased
hospitalization rates than those among TSC patients without epilepsy; however, for an inpatient
stay, TSC patients without epilepsy experienced higher total expenditures than TSC patients with
epilepsy. The increased expenditure among TSC patients without epilepsy may be attributable to
the treatment of many underlying comorbidities. Access to medical and social services and the
burden of healthcare utilization and expenditures among TSC patients have been understudied,
and future research should examine the impacts of these critical factors (socioeconomic factors,
care management, delivery, and cost patterns among individuals on public insurance, especially
Medicare and Medicaid, versus private insurance) to develop solutions and strategies that can
ensure the equitable access to healthcare.
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